MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.3500
-0.0300 (-2.17%)
As of 12:59PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.3800
Open1.4000
Bid1.34 x 4000
Ask1.35 x 1300
Day's Range1.3300 - 1.4000
52 Week Range0.9400 - 4.0500
Volume824,257
Avg. Volume2,478,383
Market Cap251.456M
Beta (3Y Monthly)3.06
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    MannKind Corporation to Hold Investor Conference Call

    WESTLAKE VILLAGE, Calif., Dec. 27, 2018 -- MannKind Corporation (NASDAQ: MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM.

  • How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own?
    Simply Wall St.27 days ago

    How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own?

    A look at the shareholders of MannKind Corporation (NASDAQ:MNKD) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...

  • Why MannKind Stock Is Plunging Today
    Motley Fool27 days ago

    Why MannKind Stock Is Plunging Today

    Shares tumble after the biopharma raises capital from a dilutive common-stock offering.

  • ACCESSWIRE27 days ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind

    NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...

  • GlobeNewswire28 days ago

    MannKind Announces Pricing of $40 Million Public Offering

    MannKind Corporation (MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of its common stock.  Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $1.50, for a gross deal size of $40.0 million, not including any future proceeds from the exercise of the warrants and before deducting the underwriting discounts and commissions and offering expenses. The shares of common stock and warrants can only be purchased together but will be issued separately and will be immediately separable upon issuance.  The offering is expected to close on December 26, 2018, subject to customary closing conditions.

  • GlobeNewswire28 days ago

    MannKind Announces Commencement of Public Offering

    MannKind Corporation (MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue and sell shares of its common stock and warrants to purchase shares of its common stock. Leerink Partners is acting as sole book-running manager for the offering. The securities described above are being offered by MannKind pursuant to a shelf registration statement on Form S-3 (No. 333-210792) previously filed by MannKind with the Securities and Exchange Commission (SEC) on April 18, 2016 and declared effective on April 27, 2016.

  • Zacks Small Cap Researchlast month

    MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target

    Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.

  • ACCESSWIRElast month

    Biotech Stocks Beating the Market

    HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Here are several biotech plays to pay close attention to in the coming sessions. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MannKind ...

  • GlobeNewswire2 months ago

    MannKind Appoints Christine Mundkur to its Board of Directors

    MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018.  Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of experience in the pharmaceutical industry to the MannKind Board. “Christine brings a tremendous wealth of experience to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation.

  • Analysts: Why United Therapeutics has had a streak of licensing deals
    American City Business Journals2 months ago

    Analysts: Why United Therapeutics has had a streak of licensing deals

    United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT

    Q3 2018 MannKind Corp Earnings Call

  • Associated Press2 months ago

    MannKind: 3Q Earnings Snapshot

    On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $4.5 million in the period. The company's shares closed ...

  • GlobeNewswire2 months ago

    MannKind Corporation Reports 2018 Third Quarter Financial Results

    Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus.

  • United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript

    UTHR earnings call for the period ending September 30, 2018.

  • GlobeNewswire3 months ago

    MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018

    WESTLAKE VILLAGE, Calif., Oct. 25, 2018 -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results.

  • GlobeNewswire3 months ago

    Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Altimmune and MannKind

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...

  • Why MannKind Corp. Soared 16.4% Tuesday
    Motley Fool3 months ago

    Why MannKind Corp. Soared 16.4% Tuesday

    The company has completed its planned transaction with United Therapeutics.

  • PR Newswire3 months ago

    United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

    RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • Here's What Sent MannKind Corporation Soaring 66.4% in September
    Motley Fool3 months ago

    Here's What Sent MannKind Corporation Soaring 66.4% in September

    A new collaboration agreement breathed life into the troubled manufacturer of inhaled insulin powder.

  • MannKind Stock History
    Motley Fool4 months ago

    MannKind Stock History

    Here's the full story of how this biopharma got to where it is today.